[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1976

Very High Dose Fluphenazine DecanoateA Controlled Trial in Chronic Schizophrenia

Author Affiliations

From St Nicholas Hospital, Newcastle upon Tyne Area Health Authority (Teaching), United Kingdom (Drs McClelland, Farquharson, and Leyburn), and the Northern Regional Health Authority, Newcastle upon Tyne (Mr Furness). Dr Schiff is a Medical (Psychiatric) Advisor at E. R. Squibb & Sons, Ltd, Twickenham, United Kingdom.

Arch Gen Psychiatry. 1976;33(12):1435-1439. doi:10.1001/archpsyc.1976.01770120039003
Abstract

• In a double-blind trial of six months' duration, a very high dose (VHD) regimen of fluphenazine decanoate (250 mg weekly) was compared with a standard dose (SD) regimen (12.5 mg weekly) in 50 chronic schizophrenic patients. The rating scales used included the Brief Psychiatric Rating Scale1 and the Wing Ward Behavior Scale.2 Both treatment groups improved during the trial, but there was no significant difference between them. The VHD regimen, however, exerted better control of the psychosis in that it had fewer patient dropouts and fewer "additional treatments" prescribed. Some of the patients receiving standard doses were probably not receiving adequate antipsychotic drug dosage. No predictors of clinical response could be defined. Extrapyramidal side effects were not significantly higher in the VHD group.

×